Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win [Yahoo! Finance]
Palvella Therapeutics, Inc. (PVLA)
Company Research
Source: Yahoo! Finance
company's underwritten public offering on Feb. 27, 2026, purchasing 4,000 shares at the offering price of $125.00 per share for a total of approximately $500,000, according to an SEC Form 4 filing Transaction summary Metric Value Shares traded Transaction value Post-transaction shares (direct) Post-transaction value (direct ownership) $21.2 million Transaction value based on SEC Form 4 reported price ($125.00); post-transaction value based on Mar. 23, 2026 market close price ($117.04). Key questions How does this purchase compare to Jenkins's historical trading activity in the company? Jenkins' April 2025 open-market purchase of 4,990 shares at roughly $20 per share was larger by share count, but the February 2026 transaction was larger in dollar terms by a significant margin, likely reflecting growing conviction as the stock has appreciated. What is the impact on Jenkins's overall stake and influence within the company? Post-transaction, Jenkins directly a
Show less
Read more
Impact Snapshot
Event Time:
PVLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVLA alerts
High impacting Palvella Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PVLA
News
- Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual MeetingGlobeNewswire
- Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal [Yahoo! Finance]Yahoo! Finance
- Palvella Therapeutics (PVLA) had its price target raised by HC Wainwright from $255.00 to $270.00. They now have a "buy" rating on the stock.MarketBeat
- Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 [TheStreet.com]TheStreet.com
- Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026GlobeNewswire
PVLA
Earnings
- 11/11/25 - Miss
PVLA
Sec Filings
- 3/20/26 - Form 4
- 3/18/26 - Form 144
- 3/2/26 - Form 4
- PVLA's page on the SEC website